Author

Iris Lodewijk

Centro de Investigaciones Energéticas, Medioambientales y TecnológicasORCID 0000-0002-5208-8249Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Carolina RubioiD· 3 shared Cristian Suárez-CabreraiD· 3 shared Jesús María ParamioiD· 3 shared Lucía MoralesiD· 3 shared Marta DueñasiD· 3 shared Álvaro Martín de BernardoiD· 2 shared Ester Munera-MaravillaiD· 2 shared Esther Montesinos· 2 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Carolina RubioORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyJournal of Experimental & Clinical Cancer ResearchPeer-reviewedFeb 23, 2026

Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models

Ester Munera-Maravilla, Mercedes Pérez-Escavy, Carolina Rubio…·Cristian Suárez-Cabrera

This study develops genetically engineered mouse models of advanced bladder cancer to investigate cell-of-origin and driver mutations, revealing subtype-specific characteristics and therapeutic responses.

DOI 10.1186/s13046-026-03677-8

mousespatial transcriptomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 27, 2025

CD44v6 Drives Tumor Aggressiveness and Chemoresistance in Bladder Cancer

Iris Lodewijk, Carolina Rubio, Pontus Eriksson…·Marta Dueñas

This study identifies CD44v6 as a driver of bladder cancer aggressiveness and chemoresistance, linking its expression to poor patient outcomes and therapeutic resistance.

DOI 10.1101/2025.08.27.672563

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyOncoImmunologyPeer-reviewedDec 19, 2024

Comprehensive Landscape of Non-muscle Invasive Bladder Cancer Tumour Microenvironment and Prognostic value of Cancer-Associated Myofibroblasts

Carmen Gómez del Cañizo, Félix Guerrero‐Ramos, Mercedes Pérez-Escavy…·Víctor G. Martínez

The paper analyzes the tumor microenvironment of NMIBC, finding that cancer-associated myofibroblasts are prognostic markers for progression and recurrence.

14 citationstop 5%

humanflow cytometry

𝕏 PostBluesky